AntriaBio Appoints Two Industry Leaders to Its Management Team

AntriaBio Appoints Two Industry Leaders to Its Management Team 
MENLO PARK, CA -- (Marketwire) -- 02/19/13 --  AntriaBio, Inc.
(OTCQB: ANTB) is pleased to announce the appointment, on January 31,
2013, of two new members to its management team: Nevan Elam, as
AntriaBio's President and Chief Executive Officer and Sankaram
Mantripragada, Ph.D., as AntriaBio's Chief Scientific Officer. 
Nevan Elam has spent his entire career starting, managing and
advising emerging growth companies in key areas of business including
finance, marketing and clinical development. Prior to joining
AntriaBio, Mr. Elam served as Chief Executive Officer of AeroSurgical
Limited, a medical device company based in Europe. Prior to that, he
directed the Pulmonary Business Unit of Nektar Therapeutics, which
was sold to Novartis in 2008. 
Mr. Elam also serves as a managing director of Konus Advisory Group,
Inc. ("Konus"), a boutique healthcare consulting and investment firm
that specializes in working with U.S. and European healthcare
organizations on business opportunities in Asia, Latin America and
the Middle East. Mr. Elam holds a J.D. from Harvard University and
Bachelor's degree from Howard University.  
Sankaram Mantripragada, Ph.D. brings to AntriaBio his strong
understanding of the diabetes market and AntriaBio's unique platform
technology. From June 2005 until October 2009, Dr. Mantripragada
served as Vice President of R&D at PR Pharmaceuticals, Inc. ("PRP").
In January 2013, AntriaBio purchased substantially all of the PRP
assets including significant technology, formulation, manufacturing,
and intellectual property assets, which together form the basis of
AntriaBio's drug development portfolio. 
"Dr. Mantripragada's history with PRP's technology and formulation
assets and his deep experience in diabetes products and markets make
him a clear choice to lead our product development efforts," said
Steve Howe, Executive Chairman of AntriaBio. Mr. Howe served as
Chairman and Chief Executive Officer of PRP from its formation in
1998 to 2010.  
Dr. Mantripragada has been an advisor to companies specializing in
diabetes, cell based therapies and cardiovascular diseases. He is
listed as an inventor on more than eight patents. 
Prior to joining PRP, Dr. Mantripragada served as
 Director of R&D at
Guidant Corporation, now part of Abbott Vascular. Prior to that, he
served as Director of R&D and VP of Scientific Development at
SkyePharma. Prior to that, he was an Assistant Professor of
Biochemistry at the University of Virginia School of Medicine. Dr.
Mantripragada obtained his Ph.D. in Molecular Biophysics from the
Indian Institute of Science and completed a postdoctoral research
program at the Max Planck Institute for Biophysical Chemistry in
About AntriaBio, Inc. 
AntriaBio is a biopharmaceutical company focused on developing novel
therapeutic products for the diabetes market. AntriaBio's development
strategy combines FDA-approved pharmaceutical agents with its
proprietary delivery technology. AntriaBio's lead product candidate
is AB101, an injectable once-a-week basal insulin for Type 1 and Type
2 diabetes. 
For more information visit: 
Safe Harbor 
This release, like many written and oral communications presented by
AntriaBio, Inc., and our authorized officers, may contain certain
forward-looking statements regarding our prospective performance and
strategies within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. We intend such forward-looking statements to be
covered by the safe harbor provisions for forward-looking statements
contained in the Private Securities Litigation Reform Act of 1995,
and are including this statement for purposes of said safe harbor
Forward-looking statements, which are based on certain assumptions
and describe future plans, strategies, and expectations of the
Company, are generally identified by use of words "anticipate,"
"believe," "estimate," "expect," "intend," "plan," "project," "seek,"
"strive," "try," or future or conditional verbs such as "could,"
"may," "should," "will," "would," or similar expressions. Our ability
to predict results or the actual effects of our plans or strategies
is inherently uncertain. Accordingly, actual results may differ
materially from anticipated results. 
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release. Except as required by applicable law or regulation,
AntriaBio undertakes no obligation to update these forward-looking
statements to reflect events or circumstances that occur after the
date on which such statements were made. 
Jamie Spring
AntriaBio, Inc. 
Press spacebar to pause and continue. Press esc to stop.